The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. (Q27853172)

From Wikidata

Jump to navigation Jump to search

scientific article

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

Language	Label	Description	Also known as
English	The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.	scientific article	The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

Statements

scholarly article

1 reference

13 November 2016

The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. (English)

1 reference

13 November 2016

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

9

object named as

Jens Huober

0 references

Pauline Wimberger

14

object named as

Pauline Wimberger

0 references

Jan Dominik Kuhlmann

5

object named as

Jan Dominik Kuhlmann

0 references

7

object named as

Jalid Sehouli

0 references

Barbara Schmalfeldt

12

object named as

Barbara Schmalfeldt

0 references

Peter Hillemanns

10

object named as

Peter Hillemanns

0 references

author name string

Hagen Sjard Bachmann

1

0 references

Werner Meier

2

0 references

Andreas du Bois

3

0 references

Rainer Kimmig

4

0 references

Winfried Siffert

6

0 references

Kerstin Wollschlaeger

8

0 references

Alexander Burges

11

0 references

Behnaz Aminossadati

13

0 references

language of work or name

0 references

publication date

November 2015

0 references

British Journal of Clinical Pharmacology

0 references

80

0 references

5

0 references

1139-48

0 references

A map of human genome variation from population-scale sequencing

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

20 March 2017

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

20 March 2017

dbSNP: the NCBI database of genetic variation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

20 March 2017

MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

7 April 2017

Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Treatment of delta hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Is there a future for prenyltransferase inhibitors in cancer therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Management of recurrent ovarian carcinoma: current status and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Lipid posttranslational modifications. Farnesyl transferase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

ConSite: web-based prediction of regulatory elements using cross-species comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Highly specific localization of promoter regions in large genomic sequences by PromoterInspector: a novel context analysis approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

The essence of SNPs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

29 September 2017

Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

2 June 2018

Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

An encouraging progress report on the treatment of progeria and its implications for atherogenesis

1 reference

https://api.crossref.org/works/10.1111%2FBCP.12688

21 January 2018

AliBaba2: context specific identification of transcription factor binding sites.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4631186

27 November 2018

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26033044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models

1 reference

https://pubmed.ncbi.nlm.nih.gov/26033044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful amplification of extremely GC-rich promoter regions using a novel 'slowdown PCR' technique

1 reference

https://pubmed.ncbi.nlm.nih.gov/26033044

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/BCP.12688

0 references

1 reference

13 November 2016

1 reference

13 November 2016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853172&oldid=1713172596"